antipyrine has been researched along with Liver Diseases in 88 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors examined the activity of N-acetyltransferase and that of microsomal P-450 isoenzymes in health and hepatic disease state by determining the acetylation phenotype and the total (CLAP) and metabolic clearances of antipyrine to form norantipyrine or N-demethylantipyrine (MCLnora), 3-hydroxymethylantipyrine (MCLhma), and 4-hydroxyantipyrine (MCLha) in 21 healthy subjects and in 33 patients with chronic liver diseases (CLD) and investigated the relationship between the activities of these two enzyme systems." | 7.69 | Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases. ( Ali, H; Dossing, M; el-Yazigi, A; Ernst, P; Raines, DA; Sieck, JO; Wahab, FA, 1995) |
| "Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases." | 7.67 | Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. ( Beppu, T; Hanano, M; Idezuki, Y; Iga, T; Kawasaki, S; Sanjo, K; Sugiura, M; Sugiyama, Y, 1988) |
| "A family with polycystic liver disease was investigated in order to evaluate the role of the liver in determining the serum high-density lipoprotein (HDL) level and its relationship to the rate of antipyrine elimination from plasma." | 7.66 | Low high-density lipoprotein and reduced antipyrine metabolism in members of a family with polycystic liver disease. ( Ehnholm, C; Luoma, PV; Sotaniemi, EA, 1980) |
| "The authors examined the activity of N-acetyltransferase and that of microsomal P-450 isoenzymes in health and hepatic disease state by determining the acetylation phenotype and the total (CLAP) and metabolic clearances of antipyrine to form norantipyrine or N-demethylantipyrine (MCLnora), 3-hydroxymethylantipyrine (MCLhma), and 4-hydroxyantipyrine (MCLha) in 21 healthy subjects and in 33 patients with chronic liver diseases (CLD) and investigated the relationship between the activities of these two enzyme systems." | 3.69 | Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases. ( Ali, H; Dossing, M; el-Yazigi, A; Ernst, P; Raines, DA; Sieck, JO; Wahab, FA, 1995) |
| "Based on the comparable Cmax but the increased AUC in patients with liver dysfunction, the initial dose of butorphanol nasal spray may not need to be adjusted." | 3.69 | The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment. ( Barbhaiya, RH; Garnett, WR; Morgenthien, EA; Shyu, WC; Vachharajani, NN, 1996) |
| "Medroxyprogesterone acetate (MPA) elimination rate was investigated in 25 patients with primary biliary cirrhosis, alcoholic cirrhosis and fatty liver." | 3.67 | Liver function and medroxyprogesterone acetate elimination in man. ( Rautio, A, 1984) |
| "Salivary antipyrine clearance was measured in 15 patients with psoriasis receiving methotrexate and related to liver biopsy changes and routine liver function tests, to determine whether antipyrine clearance could be used as a non-invasive method for monitoring liver function." | 3.67 | The use of antipyrine clearance to measure liver damage in psoriatic patients receiving methotrexate. ( Collins, M; Lawrence, CM; Paramsothy, J; Sharif, H; Shaw, P; Strange, R, 1988) |
| "Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases." | 3.67 | Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. ( Beppu, T; Hanano, M; Idezuki, Y; Iga, T; Kawasaki, S; Sanjo, K; Sugiura, M; Sugiyama, Y, 1988) |
| " Multiple relationships were revealed, but generally valid correlations for the group of liver diseases occurred only in special relationships (serum albumin level and antipyrine T1/2; serum bilirubin level and sulphadimidine T1/2)." | 3.66 | Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases. ( Beró, T; Fábián, C; Horváth, T; Jávor, T; Kádas, I; Pár, A, 1983) |
| "The elimination of pindolol was studied in 32 patients suffering from various liver diseases, mainly acute hepatitis and hepatic cirrhosis." | 3.66 | Elimination of pindolol in liver disease. ( Meier, J; Münch, U; Ohnhaus, EE, 1982) |
| "A family with polycystic liver disease was investigated in order to evaluate the role of the liver in determining the serum high-density lipoprotein (HDL) level and its relationship to the rate of antipyrine elimination from plasma." | 3.66 | Low high-density lipoprotein and reduced antipyrine metabolism in members of a family with polycystic liver disease. ( Ehnholm, C; Luoma, PV; Sotaniemi, EA, 1980) |
| "Patients with acute hepatitis and patients with compensated or decompensated cirrhosis of the liver have a decreased plasma clearance of hexobarbital." | 3.66 | [Drug metabolism in patients with liver disease (author's transl)]. ( Epping, J; Fuchshofen-Röckel, M; Heusler, H; Richter, E; Zilly, W, 1980) |
| " Drug-metabolizing capacity in cases of polycystic non-parasitic liver disease was investigated using plasma antipyrine clearance as an index." | 3.66 | Impairment of drug metabolism in polycystic non-parasitic liver disease. ( Järvensivu, PM; Luoma, PV; Sotaniemi, EA; Sotaniemi, KA, 1979) |
| "The plasma half lives of antipyrine, paracetamol, and lignocaine given by mouth were measured in 23 patients with stable chronic liver diseases of varying severity." | 3.65 | Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. ( Adjepon-Yamoah, KK; Finlayson, ND; Forrest, JA; Prescott, LF, 1977) |
| " On day 5 there were no statistically significant differences in the Cmax or tmax for ziprasidone between the two groups." | 2.69 | The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. ( Anderson, KE; Anziano, RJ; Bauer, LA; Carithens, RL; Everson, G; Johnson, A; Lasseter, KC; Smolarek, TA; Turncliff, RZ; Wilner, KD, 2000) |
| "Verapamil (CAS 52-53-9) is a calcium channel blocker with a vasodilatatory effect." | 2.68 | Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy. ( Brátová, M; Fendrich, Z; Hůlek, P; Macek, K; Vlcek, J, 1995) |
| " A Bayesian approach was developed to determine the individual pharmacokinetic parameters of phenazone." | 2.67 | Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters. ( Bouvet, O; Bressolle, F; Dubois, A; Fabre, D; Galtier, M; Goméni, R; Gris, JC; Raffanel, C, 1993) |
| " Hepatic pharmacokinetic analysis showed that both the CL int and PS were significantly decreased in the RHF rat livers." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| "Edaravone was intravenously administered to rats just before reperfusion and partial (70%) hepatectomy was performed just after reperfusion." | 1.34 | Amelioration of hepatic ischemia/reperfusion injury in the remnant liver after partial hepatectomy in rats. ( Hiranuma, S; Horikawa, S; Ito, K; Koike, Y; Noda, Y; Ozasa, H, 2007) |
| " However, because nalmefene will be primarily used in the acute care setting for reversal of opioid-induced effects, it is not likely that these alterations will necessitate a dosage modification." | 1.30 | Effects of liver disease on the disposition of the opioid antagonist nalmefene. ( Dixon, R; Frye, RF; Matzke, GR; Rabinovitz, M; Schade, R, 1997) |
| "Volumes of total liver, hepatic cysts, hepatic parenchyma, and total kidney were measured by a validated computed tomography (CT) technique." | 1.30 | Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. ( Bronner, T; Everson, GT; McKinley, C; Russ, P; Scherzinger, A; Sherstha, R; Showalter, R, 1997) |
| " We conclude that, although propranolol may have some influence on drug handling acutely, chronic administration does not interfere with hepatic drug metabolism or renal drug clearance." | 1.28 | Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease. ( Bouchier, IA; Hayes, PC, 1989) |
| " Antipyrine concentrations in saliva after oral dosing were measured by HPLC." | 1.27 | Antipyrine kinetics in liver disease and liver transplantation. ( Burckart, GJ; Gray, JA; Mehta, MU; Ptachcinski, RJ; Starzl, TE; Van Thiel, DH; Venkataramanan, R; Yang, SL, 1986) |
| "Antipyrine was chosen as a model drug." | 1.27 | Impairment of drug elimination in patients with liver disease. ( Datta, DV; Mathur, VS; Narang, AP, 1985) |
| "Antipyrine clearance was closely correlated to liver weight (r = 0." | 1.27 | Antipyrine metabolism during hepatic regeneration in the rat. ( Pilsgaard, H; Poulsen, HE, 1985) |
| "Five subjects with chronic renal failure exhibited no significant difference in salivary anti-pyrine half-life (11-7 +/- 1-9) compared to the control group, whereas six subjects with chronic liver disease and impaired hepatic function had significantly increased half-life values (42-4 +/- 10)." | 1.26 | Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy. ( Clarkson, AR; Frewin, DB; Harman, AW; Penhall, RK; Phillips, PJ; Priestly, BG, 1977) |
| "Antipyrine disposition was also measured in each subject." | 1.26 | Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease. ( Branch, RA; Halliwell, M; Homeida, M; Read, AE; Roberts, CJ, 1979) |
| "Antipyrine metabolism was normal or marginally impaired in patients with compensated cirrhosis or acute hepatitis, whereas it was frequently abnormal in those with chronic active hepatitis or advanced alcoholic liver disease." | 1.26 | Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. ( Cooksley, WG; Farrell, GC; Hart, P; Powell, LW, 1978) |
| "Antipyrine T1/2 was especially prolonged in patients with a history of more severe symptoms, but there was no correlation with the degree of elevation in urinary excretion of the porphyrin precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG)." | 1.26 | Studies in porphyria. V. Drug oxidation rates in hereditary hepatic porphyria. ( Alvares, AP; Anderson, KE; Kappas, A; Sassa, S, 1976) |
| "Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man." | 1.25 | Determinants of serum antipyrine half-lives in patients with liver disease. ( Branch, RA; Herbert, CM; Read, AE, 1973) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 66 (75.00) | 18.7374 |
| 1990's | 16 (18.18) | 18.2507 |
| 2000's | 5 (5.68) | 29.6817 |
| 2010's | 1 (1.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, P | 1 |
| Robertson, TA | 1 |
| Zhang, Q | 1 |
| Fletcher, LM | 1 |
| Crawford, DH | 1 |
| Weiss, M | 2 |
| Roberts, MS | 1 |
| Tada, S | 1 |
| Nakamoto, N | 1 |
| Kameyama, K | 1 |
| Tsunematsu, S | 1 |
| Kumagai, N | 1 |
| Saito, H | 1 |
| Ishii, H | 1 |
| FLOREZ TASCON, FJ | 1 |
| SERRA GARCIA, E | 1 |
| DURAN-CANTERO, J | 1 |
| RIVERO VALENZUELA, F | 1 |
| Ninomiya, M | 1 |
| Shimada, M | 1 |
| Harada, N | 1 |
| Soejima, Y | 1 |
| Suehiro, T | 1 |
| Maehara, Y | 1 |
| Taniguchi, M | 1 |
| Uchinami, M | 1 |
| Doi, K | 1 |
| Yoshida, M | 1 |
| Sasaki, H | 1 |
| Tamagawa, K | 1 |
| Horiuchi, T | 1 |
| Tanaka, K | 1 |
| Hiranuma, S | 1 |
| Ito, K | 1 |
| Noda, Y | 1 |
| Ozasa, H | 1 |
| Koike, Y | 1 |
| Horikawa, S | 1 |
| Tygstrup, N | 2 |
| Vilstrup, H | 1 |
| Bircher, J | 1 |
| Vesell, ES | 2 |
| Farrell, GC | 4 |
| Zaluzny, L | 1 |
| Rautio, A | 1 |
| Kettner, W | 2 |
| Banditt, P | 1 |
| Walther, H | 1 |
| Horváth, T | 1 |
| Pár, A | 1 |
| Beró, T | 1 |
| Kádas, I | 1 |
| Fábián, C | 1 |
| Jávor, T | 1 |
| Mokros, W | 1 |
| Bonkovsky, HL | 1 |
| Mitchell, WJ | 1 |
| Healey, JF | 1 |
| Loginov, AS | 3 |
| Bendikov, EA | 4 |
| Otunbaeva, DI | 1 |
| Rykova, IA | 1 |
| Petrakov, AV | 4 |
| Narang, AP | 2 |
| Mathur, VS | 2 |
| Koshy, A | 1 |
| Nath, N | 1 |
| Datta, DV | 2 |
| Okolicsànyi, L | 1 |
| Orlando, R | 1 |
| Lirussi, F | 1 |
| Naccarato, R | 1 |
| Dal Brun, G | 1 |
| Ohnhaus, EE | 3 |
| Münch, U | 2 |
| Meier, J | 2 |
| Kuntz, HD | 1 |
| Meessen, D | 1 |
| May, B | 2 |
| Luoma, PV | 3 |
| Sotaniemi, EA | 3 |
| Ehnholm, C | 1 |
| Takashi, M | 1 |
| Musha, H | 1 |
| Tsuchiya, S | 1 |
| Gotoh, N | 1 |
| Takayasu, K | 1 |
| Suzuki, N | 1 |
| Kotoda, K | 1 |
| Okuda, K | 1 |
| Richter, E | 1 |
| Epping, J | 1 |
| Fuchshofen-Röckel, M | 1 |
| Heusler, H | 1 |
| Zilly, W | 1 |
| Liubchenko, PN | 1 |
| Gorenkov, RV | 1 |
| el-Yazigi, A | 1 |
| Raines, DA | 1 |
| Wahab, FA | 1 |
| Sieck, JO | 1 |
| Ernst, P | 1 |
| Ali, H | 1 |
| Dossing, M | 1 |
| Vlcek, J | 1 |
| Macek, K | 1 |
| Hůlek, P | 1 |
| Brátová, M | 1 |
| Fendrich, Z | 1 |
| Boothe, DM | 1 |
| Cullen, JM | 1 |
| Calvin, JA | 1 |
| Jenkins, WL | 1 |
| Brown, SA | 1 |
| Green, RA | 1 |
| Corrier, DE | 1 |
| Fabre, D | 1 |
| Bressolle, F | 1 |
| Goméni, R | 1 |
| Bouvet, O | 1 |
| Dubois, A | 1 |
| Raffanel, C | 1 |
| Gris, JC | 1 |
| Galtier, M | 1 |
| Vachharajani, NN | 1 |
| Shyu, WC | 1 |
| Garnett, WR | 1 |
| Morgenthien, EA | 1 |
| Barbhaiya, RH | 1 |
| Frye, RF | 1 |
| Matzke, GR | 1 |
| Schade, R | 1 |
| Dixon, R | 1 |
| Rabinovitz, M | 1 |
| Sherstha, R | 1 |
| McKinley, C | 1 |
| Russ, P | 1 |
| Scherzinger, A | 1 |
| Bronner, T | 1 |
| Showalter, R | 1 |
| Everson, GT | 1 |
| Tanaka, E | 3 |
| Yasuhara, H | 1 |
| Breimer, DD | 2 |
| Zhu, M | 1 |
| Lin, KF | 1 |
| Yeung, RY | 1 |
| Li, RC | 1 |
| Everson, G | 1 |
| Lasseter, KC | 1 |
| Anderson, KE | 2 |
| Bauer, LA | 1 |
| Carithens, RL | 1 |
| Wilner, KD | 1 |
| Johnson, A | 1 |
| Anziano, RJ | 1 |
| Smolarek, TA | 1 |
| Turncliff, RZ | 1 |
| Paumgartner, G | 1 |
| Harman, AW | 1 |
| Penhall, RK | 1 |
| Priestly, BG | 1 |
| Frewin, DB | 1 |
| Phillips, PJ | 1 |
| Clarkson, AR | 1 |
| Stevenson, IH | 2 |
| Pirttiaho, H | 1 |
| Capel, ID | 1 |
| Grant, EC | 1 |
| Dorrell, HM | 1 |
| Pinnock, MH | 1 |
| Rose, FC | 1 |
| Williams, DC | 1 |
| Cooksley, WG | 3 |
| Powell, LW | 3 |
| Homeida, M | 2 |
| Roberts, CJ | 2 |
| Halliwell, M | 2 |
| Read, AE | 5 |
| Branch, RA | 5 |
| Järvensivu, PM | 1 |
| Sotaniemi, KA | 1 |
| Hart, P | 1 |
| McLean, A | 2 |
| du Souich, P | 1 |
| Gibaldi, M | 1 |
| Prescott, LF | 3 |
| Forrest, JA | 3 |
| Adjepon-Yamoah, KK | 3 |
| Finlayson, ND | 3 |
| Hepner, GW | 2 |
| Lipton, A | 1 |
| Harvey, HA | 1 |
| Wilkinson, GR | 1 |
| Schenker, S | 1 |
| James, JA | 3 |
| Alvares, AP | 1 |
| Sassa, S | 1 |
| Kappas, A | 1 |
| Andreasen, PB | 2 |
| Greisen, G | 1 |
| Etoh, H | 1 |
| Ishikawa, A | 1 |
| Nakano, M | 1 |
| Misawa, S | 1 |
| St Peter, JV | 1 |
| Awni, WM | 1 |
| Wensing, G | 1 |
| Hoensch, HP | 1 |
| Schellens, JH | 1 |
| Janssens, AR | 1 |
| van der Wart, JH | 1 |
| van der Velde, EA | 1 |
| Millikan, WJ | 1 |
| Henderson, JM | 1 |
| Stewart, MT | 1 |
| Warren, WD | 1 |
| Marsh, JW | 1 |
| Galloway, JR | 1 |
| Jennings, H | 1 |
| Kawasaki, S | 2 |
| Dodson, TF | 1 |
| Perlino, CA | 1 |
| Hayes, PC | 1 |
| Bouchier, IA | 1 |
| Herrick, A | 1 |
| McColl, KE | 2 |
| McLellan, A | 1 |
| Moore, MR | 2 |
| Brodie, MJ | 2 |
| Goldberg, A | 2 |
| Paramsothy, J | 1 |
| Strange, R | 1 |
| Sharif, H | 1 |
| Collins, M | 1 |
| Shaw, P | 1 |
| Lawrence, CM | 1 |
| Hartleb, M | 2 |
| Markiewicz, A | 1 |
| Rudzki, K | 1 |
| Nowak, S | 1 |
| Bołdys, H | 1 |
| Kacperek, T | 2 |
| Sugiyama, Y | 1 |
| Iga, T | 1 |
| Hanano, M | 1 |
| Beppu, T | 1 |
| Sugiura, M | 1 |
| Sanjo, K | 1 |
| Idezuki, Y | 1 |
| Altmann, HW | 1 |
| Mehta, MU | 1 |
| Venkataramanan, R | 1 |
| Burckart, GJ | 1 |
| Ptachcinski, RJ | 1 |
| Yang, SL | 1 |
| Gray, JA | 1 |
| Van Thiel, DH | 1 |
| Starzl, TE | 1 |
| Birnie, GG | 1 |
| Thompson, GG | 1 |
| Kel'nia, ZhA | 1 |
| Gugler, R | 1 |
| von Mandach, U | 1 |
| Jost, G | 1 |
| Preisig, R | 1 |
| Poulsen, HE | 1 |
| Pilsgaard, H | 1 |
| Fujii, T | 1 |
| McEwen, J | 1 |
| Ackermann, E | 1 |
| Renger, F | 1 |
| Dökert, B | 1 |
| Walther, M | 1 |
| Herbert, CM | 1 |
| Helmstaedt, D | 1 |
| Büstgens, L | 1 |
| Ranek, L | 1 |
| Statland, BE | 1 |
| Breckenridge, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia[NCT03781115] | Phase 1 | 24 participants (Anticipated) | Interventional | 2017-11-20 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for antipyrine and Liver Diseases
| Article | Year |
|---|---|
Diagnostic procedures in the evaluation of hepatic diseases. Functional evaluation of the hepatocyte.
Topics: Aminopyrine; Ammonia; Antipyrine; Bile Acids and Salts; Bilirubin; Galactose; Humans; Liver Diseases | 1983 |
Quantitative assessment of deranged hepatic function: a missed opportunity?
Topics: Adult; Aminopyrine; Antipyrine; Blood Circulation; Breath Tests; Chronic Disease; Galactose; Humans; | 1983 |
Noninvasive assessment in vivo of hepatic drug metabolism in health and disease.
Topics: Adult; Aminopyrine; Animals; Antipyrine; Breath Tests; Humans; Liver; Liver Cirrhosis; Liver Disease | 1984 |
[Antipyrine test in evaluating the detoxifying function of the liver in chronic diseases].
Topics: Adult; Aged; Antipyrine; Humans; Kinetics; Liver; Liver Diseases; Middle Aged; Saliva; Time Factors | 1982 |
[Evaluation of liver function in liver diseases using drugs as indicators].
Topics: Aminopyrine; Antipyrine; Erythromycin; Humans; Lidocaine; Liver; Liver Diseases; Liver Function Test | 1997 |
In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease.
Topics: Aminopyrine; Antipyrine; Breath Tests; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome | 1997 |
Factors influencing antipyrine elimination.
Topics: Aging; Anemia, Hypochromic; Antipyrine; Chemical Phenomena; Chemistry; Drug Interactions; Half-Life; | 1977 |
Drug metabolism in liver disease.
Topics: Acetaminophen; Acute Disease; Antipyrine; Chemical and Drug Induced Liver Injury; Chronic Disease; H | 1975 |
Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.
Topics: Antipyrine; Humans; Liver; Liver Diseases; Liver Function Tests | 1991 |
[The antipyrine test: its 35-year history and prospects].
Topics: Antipyrine; Humans; Liver Diseases; Liver Function Tests; Time Factors | 1987 |
Drug metabolism.
Topics: Adult; Aged; Alcohol Oxidoreductases; Animals; Antipyrine; Dogs; Enzyme Induction; Enzyme Inhibitors | 1972 |
5 trials available for antipyrine and Liver Diseases
| Article | Year |
|---|---|
[Pharmaco-metabolic activity in chronic hepatopathies: influence of treatment with UDPG].
Topics: Adult; Aged; Antipyrine; Chronic Disease; Clinical Trials as Topic; Female; Hepatitis; Humans; Liver | 1980 |
Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy.
Topics: Adult; Aged; Antipyrine; Breath Tests; Female; Half-Life; Humans; Hypertension, Portal; Liver Diseas | 1995 |
Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.
Topics: Adult; Aged; Antipyrine; Bayes Theorem; Body Fluid Compartments; Chronic Disease; Female; Humans; Li | 1993 |
The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Antipyrine; Area Under Curve; Female; Humans; Liver C | 2000 |
Major determinants of drug disposition in chronic liver disease: a study with indocyanine green and antipyrine [proceedings].
Topics: Antipyrine; Chronic Disease; Humans; Indocyanine Green; Liver; Liver Diseases | 1975 |
72 other studies available for antipyrine and Liver Diseases
| Article | Year |
|---|---|
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
Clinical usefulness of edaravone for acute liver injury.
Topics: Animals; Antipyrine; Apoptosis; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Edarav | 2003 |
[Oral Ripason treatment of various types of minor hepatic insufficiency].
Topics: Administration, Oral; Adrenal Cortex Hormones; Antipyrine; Hepatic Insufficiency; Humans; Liver Dise | 1962 |
The hydroxyl radical scavenger MCI-186 protects the liver from experimental cold ischaemia-reperfusion injury.
Topics: Animals; Antipyrine; Cold Temperature; Edaravone; Free Radical Scavengers; Hydroxyl Radical; Interle | 2004 |
Edaravone reduces ischemia-reperfusion injury mediators in rat liver.
Topics: Animals; Antipyrine; Aspartate Aminotransferases; E-Selectin; Edaravone; Free Radical Scavengers; Li | 2007 |
Amelioration of hepatic ischemia/reperfusion injury in the remnant liver after partial hepatectomy in rats.
Topics: Animals; Antipyrine; Edaravone; Free Radical Scavengers; Gene Expression Regulation; Hepatectomy; In | 2007 |
Accuracy and clinical utility of simplified tests of antipyrine metabolism.
Topics: Adult; Antipyrine; Female; Humans; Kinetics; Liver; Liver Diseases; Male; Metabolic Clearance Rate; | 1984 |
Liver function and medroxyprogesterone acetate elimination in man.
Topics: Antipyrine; Fatty Liver; Female; Humans; Liver; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary | 1984 |
[Determination of hepatic metabolic capacity: antipyrine pharmacokinetics in circulatory liver damage due to cardiac insufficiency].
Topics: Aged; Antipyrine; Dose-Response Relationship, Drug; Female; Half-Life; Heart Diseases; Heart Valve D | 1983 |
Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
Topics: Adult; Antipyrine; Bilirubin; Chronic Disease; Enzyme Induction; Female; Glucaric Acid; Humans; Kine | 1983 |
[Preoperative examinations by internists before reoperation].
Topics: Antipyrine; Clinical Enzyme Tests; Heart Diseases; Humans; Liver; Liver Diseases; Liver Function Tes | 1984 |
Effect of hemochromatosis on hepatic cytochrome P450 and antipyrine metabolism in humans.
Topics: Antipyrine; Cytochrome P-450 Enzyme System; Hemochromatosis; Humans; Iron; Kinetics; Liver Diseases | 1984 |
Drug metabolism in non-cirrhotic portal fibrosis and other liver diseases.
Topics: Adolescent; Adult; Aminopyrine N-Demethylase; Antipyrine; Drug Therapy; Female; Glucuronosyltransfer | 1981 |
Elimination of pindolol in liver disease.
Topics: Adolescent; Adult; Aged; Antipyrine; Female; Half-Life; Humans; Kinetics; Liver Cirrhosis; Liver Dis | 1982 |
[Hepatic elimination of indocyanine green and antipyrine in patients with chronic liver disease].
Topics: Antipyrine; Chronic Disease; Hepatitis; Humans; Indocyanine Green; Liver Diseases; Liver Function Te | 1982 |
Low high-density lipoprotein and reduced antipyrine metabolism in members of a family with polycystic liver disease.
Topics: Adult; Antipyrine; Apoproteins; Cysts; Female; Humans; Lipids; Lipoproteins, HDL; Liver; Liver Disea | 1980 |
[Clinical significance of antipyrine metabolism in patients with various liver diseases (author's transl)].
Topics: Antipyrine; Half-Life; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases; Liver Function Tests | 1981 |
Saliva and plasma clearance of antipyrine as reflectors of liver function.
Topics: Adult; Antipyrine; Female; Half-Life; Humans; Kinetics; Liver; Liver Diseases; Liver Function Tests; | 1981 |
[Drug metabolism in patients with liver disease (author's transl)].
Topics: Acute Disease; Adult; Antipyrine; Biological Availability; Biotransformation; Cholestasis; Female; H | 1980 |
[Functional state of the liver in workers exposed to multi-component chemical mixture in the production of plastic construction materials].
Topics: Adult; Antipyrine; Chemical and Drug Induced Liver Injury; Construction Materials; Diethylhexyl Phth | 1995 |
Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases.
Topics: Acetylation; Adult; Antipyrine; Arylamine N-Acetyltransferase; Chronic Disease; Cytochrome P-450 Enz | 1995 |
[Lipid peroxidation markers in the exhaled breath and microsomal oxidation in patients with chronic diffuse liver diseases].
Topics: Adult; Antipyrine; Biomarkers; Breath Tests; Butanes; Chronic Disease; Female; Humans; Lipid Peroxid | 1995 |
Antipyrine and caffeine dispositions in clinically normal dogs and dogs with progressive liver disease.
Topics: Analysis of Variance; Animals; Antipyrine; Caffeine; Chemical and Drug Induced Liver Injury; Chromat | 1994 |
The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Topics: Administration, Intranasal; Adult; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anti | 1996 |
Effects of liver disease on the disposition of the opioid antagonist nalmefene.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Case-Control Studies; Female; Gala | 1997 |
Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease.
Topics: Antipyrine; Caffeine; Cysts; Estrogen Replacement Therapy; Female; Hormones; Humans; Kidney; Liver; | 1997 |
Evaluation of the protective effects of Schisandra chinensis on Phase I drug metabolism using a CCl4 intoxication model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Area Under Curve; Carbon Tetrachloride | 1999 |
[Drug metabolism in liver diseases].
Topics: Antipyrine; Biological Availability; Biotransformation; Diazepam; Humans; Liver; Liver Diseases; Pha | 1979 |
Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
Topics: Adult; Aged; Anticonvulsants; Antipyrine; Chronic Disease; Female; Half-Life; Humans; Kidney Failure | 1977 |
Liver size in evaluating drug metabolizing capacity in man.
Topics: Adult; Aged; Antipyrine; Biopsy; Biotransformation; Cytochrome P-450 Enzyme System; Enzyme Induction | 1979 |
Disturbed liver function in migraine patients.
Topics: Adult; Antipyrine; Female; Humans; Liver Diseases; Liver Function Tests; Middle Aged; Migraine Disor | 1979 |
Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes.
Topics: Antipyrine; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 Enzyme System; Ethylmorphine-N-Demethyla | 1979 |
Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.
Topics: Aged; Antipyrine; Body Weight; Chronic Disease; Humans; Liver; Liver Diseases; Liver Function Tests; | 1979 |
Enhancement of hepatic drug metabolism by glutethimide in patients with liver disease.
Topics: Adult; Aged; Antipyrine; Female; Glutethimide; Half-Life; Humans; Liver; Liver Diseases; Male; Middl | 1979 |
Impairment of drug metabolism in polycystic non-parasitic liver disease.
Topics: Adult; Antipyrine; Cysts; Female; Half-Life; Humans; Liver Diseases; Male; Metabolic Clearance Rate; | 1979 |
Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.
Topics: Acute Disease; Antipyrine; Ascites; Biotransformation; Chemical and Drug Induced Liver Injury; Chole | 1978 |
Noninvasive kinetic approach to the estimation of total hepatic blood flow and shunting in chronic liver disease--a hypothesis.
Topics: Antipyrine; Chronic Disease; Humans; Indocyanine Green; Kinetics; Liver; Liver Circulation; Liver Di | 1979 |
Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.
Topics: Acetaminophen; Adult; Aged; Antipyrine; Chronic Disease; Female; Half-Life; Humans; Kinetics; Lidoca | 1977 |
Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.
Topics: Adult; Aged; Aminopyrine; Anticonvulsants; Antipyrine; Breath Tests; Diazepam; Half-Life; Humans; In | 1977 |
Value of liver volume measurement in the study of antipyrine kinetics in liver disease [proceedings].
Topics: Adolescent; Adult; Aged; Antipyrine; Humans; Kinetics; Liver; Liver Diseases; Middle Aged | 1977 |
[Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
Topics: Antipyrine; Fatty Liver; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases; Pindolol | 1976 |
Proceedings: Antipyrine, lingocaine and paracetamol metabolism in chronic liver disease.
Topics: Acetaminophen; Adult; Aged; Antipyrine; Chronic Disease; Female; Humans; Lidocaine; Liver Diseases; | 1975 |
Studies in porphyria. V. Drug oxidation rates in hereditary hepatic porphyria.
Topics: Adult; Aminolevulinic Acid; Antipyrine; Erythrocytes; Female; Half-Life; Humans; Hydroxymethylbilane | 1976 |
Phenazone metabolism in patients with liver disease.
Topics: Adult; Aged; Antipyrine; Creatinine; Galactose; Humans; Injections, Intravenous; Kinetics; Liver Dis | 1976 |
The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
Topics: Adult; Aged; Antipyrine; Bilirubin; Chronic Disease; Female; Half-Life; Humans; Indocyanine Green; K | 1976 |
Influence of liver damage on antipyrine metabolite formation in rats.
Topics: 1-Naphthylisothiocyanate; Animals; Antipyrine; Carbon Tetrachloride; Chemical and Drug Induced Liver | 1991 |
Antipyrine elimination and hepatic microsomal enzyme activity in patients with liver disease.
Topics: 7-Alkoxycoumarin O-Dealkylase; Adult; Aged; Aged, 80 and over; Antipyrine; Female; Humans; Liver; Li | 1990 |
Use of metabolite AUC data in bioavailability studies to discriminate between absorption and first-pass extraction.
Topics: Absorption; Antipyrine; Biological Availability; Caffeine; Diphenhydramine; Dose-Response Relationsh | 1990 |
Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach.
Topics: Adult; Aged; Antipyrine; Female; Hexobarbital; Humans; Liver Diseases; Male; Metabolic Clearance Rat | 1989 |
Change in hepatic function, hemodynamics, and morphology after liver transplant. Physiological effect of therapy.
Topics: Adult; Amino Acids; Antipyrine; Bilirubin; Biopsy; Costs and Cost Analysis; Female; Follow-Up Studie | 1989 |
Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
Topics: Acetaminophen; Adult; Aged; Antipyrine; Chronic Disease; Drug Administration Schedule; Female; Human | 1989 |
Effect of haem arginate therapy on porphyrin metabolism and mixed function oxygenase activity in acute hepatic porphyria.
Topics: Acute Disease; Adult; Antipyrine; Arginine; Cytochrome P-450 Enzyme System; Depression, Chemical; Fe | 1987 |
The use of antipyrine clearance to measure liver damage in psoriatic patients receiving methotrexate.
Topics: Adult; Antipyrine; Biopsy; Chemical and Drug Induced Liver Injury; Female; Humans; Liver; Liver Dise | 1988 |
[Clinical variability of hepatic clearance of antipyrine and Tc-99m-HIDA in healthy persons and in those with liver diseases. II. Effect of propranolol].
Topics: Adult; Antipyrine; Circadian Rhythm; Contrast Media; Female; Humans; Imino Acids; Liver; Liver Disea | 1987 |
Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
Topics: Adult; Aged; Antipyrine; Chronic Disease; Female; Galactose; Galactosemias; Hepatitis; Humans; Indoc | 1988 |
Morphological changes in the liver due to phenazone and its derivatives.
Topics: Antipyrine; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Fatty Liver; Granulom | 1986 |
Antipyrine kinetics in liver disease and liver transplantation.
Topics: Administration, Oral; Adolescent; Adult; Antipyrine; Chromatography, High Pressure Liquid; Female; H | 1986 |
Antipyrine metabolism in acute hepatic porphyria in relapse and remission.
Topics: 5-Aminolevulinate Synthetase; Adolescent; Adult; Aged; Aminolevulinic Acid; Antipyrine; Cytochrome P | 1987 |
[Monooxigenase activity in liver diseases (study based on data of antipyrine metabolism)].
Topics: Adult; Aged; Antipyrine; Cytochrome P-450 Enzyme System; Female; Humans; Inactivation, Metabolic; Ki | 1987 |
[Antipyrine excretion and aminopyrine breath test: use and significance in the assessment of liver function].
Topics: Aminopyrine; Antipyrine; Biotransformation; Breath Tests; Humans; Liver Diseases; Liver Function Tes | 1987 |
[Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
Topics: Adolescent; Adult; Aged; Aminopyrine; Antipyrine; Breath Tests; Carbon Dioxide; Chromatography, High | 1985 |
Impairment of drug elimination in patients with liver disease.
Topics: Adult; Antipyrine; Female; Half-Life; Humans; Kinetics; Liver Diseases; Liver Function Tests; Male; | 1985 |
Antipyrine metabolism during hepatic regeneration in the rat.
Topics: Animals; Antipyrine; Edaravone; Female; Liver Diseases; Liver Regeneration; Organ Size; Rats; Rats, | 1985 |
Editorial: Drug metabolism in disease.
Topics: Alanine Transaminase; Anti-Bacterial Agents; Antipyrine; Half-Life; Humans; Kidney; Kidney Diseases; | 1974 |
Letter: Drug metabolism in disease.
Topics: Aminopyrine; Antipyrine; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; Half-Life; Humans; Live | 1974 |
Effects of vitamin E on toxicoderma associated with liver damage. Case report.
Topics: Adult; Alkanesulfonates; Antipyrine; Aspirin; Chloramphenicol; Female; Humans; Liver Diseases; Skin | 1972 |
Proceedings: The influence of chronic liver disease on the elimination of d-propranolol, anti-pyrine, and indocyanine green.
Topics: Administration, Oral; Antipyrine; Bilirubin; Chronic Disease; Humans; Indocyanine Green; Liver; Live | 1974 |
[Aminophenazone half life in patients with chronic liver parenchyma disorders].
Topics: Aminopyrine; Animals; Antipyrine; Chronic Disease; Fatty Liver; Female; Half-Life; Hepatitis; Humans | 1972 |
Determinants of serum antipyrine half-lives in patients with liver disease.
Topics: Adult; Alkaline Phosphatase; Antipyrine; Aspartate Aminotransferases; Bilirubin; Half-Life; Hepatiti | 1973 |
Proceedings: The relation between cytochrome P450 in liver biopsies and drug metabolism in patients with liver disease and in morphine addiction.
Topics: Antipyrine; Biopsy; Cytochrome P-450 Enzyme System; Humans; Liver; Liver Diseases; Morphine Dependen | 1974 |
Clearance of antipyrine-dependence of quantitative liver function.
Topics: Adult; Antipyrine; Female; Galactose; Humans; Liver; Liver Diseases; Liver Function Tests; Male; Met | 1974 |
Pathophysiological factors influencing drug kinetics.
Topics: Absorption; Age Factors; Antipyrine; Chloral Hydrate; Environmental Exposure; Ethanol; Female; Human | 1971 |